November 17, 2025 7:42am

With 7 negative and 3 positive closes, due a “pos”

With Fed’s questionable interest rate decision exacerbating pressure on the market

As the ripple effects of the shutdown are expected to last longer

Pre-open Signals: 4 Positive and 4 Negative Indications and a lot of drops

Never leave an investor uninformed … I say what others won’t, so you can do what others can’t!

“I hate to be considered negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but, I am mostly EARLY!”

Friday’s RMi Closing Bell: More pain … https://www.regmedinvestors.com/articles/14197   

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

 

Monday: The pre-open Dow futures are DOWN -0.02% or (-9 points), the S&P futures are UP +0.09% or (+15 points) and the Nasdaq futures are UP +0.18% or (+45 points)

  • Stock futures were mixed yet slightly positive, Monday 11/17,
  • European markets started up yet experienced the “drain” as time spent,
  • Asia Pacific markets traded mixed.

 

Henry’omics: We need to more than consider the market’s setting to grasp the micro re “our” universe of cell and gene therapy companies

  • Friday: The Dow closed DOWN -309.74 points or -0.65%, the S&P closed DOWN -3.38 points or -0.05% while the Nasdaq closed UP +30.234 points or +0.13%
  • Thursday: The Dow closed DOWN -797.60 points or -1.65%, the S&P closed DOWN -113.43 points or -1.66% while the Nasdaq closed DOWN -536.102 points or -2.29%
  • Wednesday: The Dow closed UP +326.86 points or +0.68%, the S&P closed UP +4.31 points or +0.06% while the Nasdaq closed DOWN -61.844 points or -0.26%
  • Tuesday: The Dow closed UP +559.33 points or +1.18%, the S&P closed UP +14.18 points or +0.21% while the Nasdaq closed DOWN -58.874 points or -0.25%
  • Monday: The Dow closed UP +381.53 points or +0.81%, the S&P closed UP +103.63 points or +1.54% while the Nasdaq closed UP +522.637 points or +2.27%
  • Last week: The S&P 500 was up +0.1%, the Dow +0.3% and the Nasdaq was down -0.5%.
  • The previous week: The S&P 500 was down -1.7%, the Dow -1.3% and the Nasdaq -3%
  • Last month: the S&P 500 was up +2.3%, the Nasdaq’s +4.7% and the Dow’s is up +2.5%.

 

Q4 – November, 3 positive and 7 negative sessions

  • October, 1 neutral, 10 positive and 12 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

It's good to know, isn't what your fund or broker won't ...

Ionis Pharmaceuticals (IONS) closed up +$1.71 after Thursday-$2.83 after Wednesday’s+$0.22, Tuesday’s +$2.91 and Monday’s -$4.01 with a negative -$1.07 or -1.50% pre-open

Precigen (PGEN) closed up +$0.99 with a positive +$0.03 or +0.62% pre-open

Wave Life Sciences (WVE +$0.41 with a positive +$0.07 or +0.09% pre-open

Ultragenyx Pharmaceuticals (RARE) closed up +$0.18 after Thursday-$0.63 after Wednesday’s +$0.28, Tuesday’s +$1.31, and Monday’s +$1.31 with a positive +$1.36 or +4.11% pre-open

Arrowhead Pharma (ARWR) closed up +$0.12 with a negative -$0.06 or -0.15% pre-open

Alnylam Pharmaceuticals (ALNY) closed down -$4.81 after Thursday +$1.23, Wednesday’s +$0.79, Tuesday’s +$10.25 and Monday’s -$1.00 with a negative -$2.00 or -0.45% pre-open

IQVIA Holdings (IQV) closed down -$2.95 after Thursday +$2.67, Wednesday’s +$2.34, Tuesday’s +$5.47 and Monday’s +$2.59 with a positive +$3.08 or +1.40% pre-open

uniQure NV (QURE) closed down -$0.46 after Thursday +$0.22, Wednesday’s -$0.72 and Tuesday’s +$4.57 with a negative -$1.08 or -3.61% pre-open

 

The BOTTOM LINE: Still feeling the what … uncertainty!

The 11th trading session of November followed a Friday negative close after a mixed week.

A good for the sector: another M&A …

  • Merck (MRK) agreeing to acquire Cidara Therapeutics (CDTX +$111.72 or +105.41% to $217.71 with an aftermarket of -$0.50 or -0.23%), known for pioneering an antiviral drug against the flu. CDTX is valued at $9.2 billion after recording a 52-week high on November 14.

Earnings are still coming!

  • Q3 Earnings coming: Arrowhead Pharma (ARWR) FY25 results on 11/25

Expect earnings’ results that meet, beat or miss revenue estimates, EPS as to pricing expectations, consensus … sector earnings while LPS (loss-per-share) assumes adjustments

Welcome to my world of defining the “grey’ in our universe!

  • As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

November to understand the flow:

This week:

  • 11/14 - Friday closed negative with 19 positive, 21 negative and 0 flats
  • 11/13 – Thursday closed negative with 8 positive, 32 negative and 0 flat
  • 11/12 – Wednesday closed negative with 18 positive, 22 negative and 0 flat
  • 11/11 – Tuesday closed positive with 34 positive, 4 negative and 2 flats
  • 11/10 - Monday closed positive with 26 positive, 14 negative and 0 flats

Last week:

  • 11/7 – Friday closed negative with 16 positive, 24 negative and 0 flat
  • 11/6 – Thursday closed negative with 15 positive, 24 negative and 1 flat
  • 11/5 - Wednesday closed positive with 20 positive, 18 negative and 2 flats
  • 11/4 – Tuesday closed negative with 10 positive, 30 negative and 0 flat
  • 11/3 – Monday closed negative with 10 positive, 26 negative and 4 flats

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.